Sermorelin

GRF (1-29) · formerly Geref

First 29 amino acids of GHRH; previously FDA-approved for pediatric GH deficiency, discontinued in 2008.

Unapproved / researchGrowth Hormone

Not FDA-approved. Previously FDA-approved (Geref, withdrawn 2008). Currently available in the US via compounding. This page describes research and public discussion; it is not a recommendation to use.

Overview

Sermorelin was approved (Geref) for diagnosing and treating idiopathic GH deficiency in children. The manufacturer discontinued it for commercial reasons, not safety. It is widely compounded for ‘anti-aging’ use in adults, which lacks strong evidence.

Mechanism of action

GHRH receptor agonist that stimulates natural, pulsatile GH release subject to somatostatin feedback.

Benefits & evidence ratings

Increased growth velocity in GH-deficient childrenA Established / approved

Raised GH/IGF-1 in older adults (small trials)B Human clinical data

Anti-aging, body-composition benefits in adultsD Anecdotal / community

Dosing

Doses show what has been studied or discussed — not guidance. Always follow your prescriber.

Source	Dose	Frequency	Duration	Route
Former Geref label (pediatric) A Established / approved	0.03 mg/kg	Nightly	Long-term	Subcutaneous
Older-adult trials B Human clinical data	~1–2 mg	Nightly	16 weeks	Subcutaneous

Clinical trials & studies

Review1999
Sermorelin: a review of its use in GH deficiency (BioDrugs)
Clinical pharmacology and pediatric efficacy.

Safety

Side effects

Injection-site pain/flushing
Headache, dizziness

Contraindications

Active cancer
Hypothyroidism (untreated)
Pregnancy

Interactions

Glucocorticoids
Somatostatin analogues

Long-term safety

Pediatric long-term data exist; adult anti-aging use is not well studied.

Regulatory status

Unapproved / research

Previously FDA-approved (Geref, withdrawn 2008). Currently available in the US via compounding.

FAQ

Commonly discussed alongside

Ipamorelin

Listing a combination does not mean it has been studied or is safe.